Dominic Piscitelli Sells 52,000 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli sold 52,000 shares of Oric Pharmaceuticals stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $13.51, for a total transaction of $702,520.00. Following the transaction, the chief financial officer directly owned 68,148 shares of the company’s stock, valued at $920,679.48. The trade was a 43.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Dominic Piscitelli also recently made the following trade(s):

• On Tuesday, December 16th, Dominic Piscitelli sold 10,720 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $9.06, for a total transaction of $97,123.20.

Oric Pharmaceuticals Trading Down 0.4%

Shares of NASDAQ:ORIC opened at $13.45 on Friday. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of -8.85 and a beta of 1.35. Oric Pharmaceuticals, Inc. has a 12 month low of $3.90 and a 12 month high of $14.93. The firm’s 50-day moving average is $10.39 and its 200 day moving average is $11.00.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its earnings results on Monday, February 23rd. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.04. As a group, equities analysts forecast that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Citigroup lifted their target price on Oric Pharmaceuticals from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday. Piper Sandler began coverage on shares of Oric Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “overweight” rating and a $22.00 price target on the stock. Evercore began coverage on shares of Oric Pharmaceuticals in a research report on Thursday, November 20th. They issued an “outperform” rating and a $25.00 price objective for the company. Wolfe Research began coverage on shares of Oric Pharmaceuticals in a research note on Tuesday, November 18th. They issued a “peer perform” rating on the stock. Finally, HC Wainwright lifted their price target on shares of Oric Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.20.

Oric Pharmaceuticals News Roundup

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised quarterly and FY2026 EPS estimates, narrowed the FY loss forecast (to ($1.28) from ($1.52)), kept a “Buy” rating and raised its price target to $25 — a material analyst upgrade supporting upside. Read More.
• Positive Sentiment: Oric reported a Q4 earnings beat (EPS -$0.30 vs. -$0.34 consensus), which acted as a near-term catalyst and likely drove recent buying interest. Read More.
• Positive Sentiment: Multiple broker actions (Wedbush Outperform; Piper Sandler, JPMorgan and others with overweight/buy calls and higher targets) have created a bullish analyst consensus — Zacks highlights the mean price target implying ~58% upside, which can attract momentum buyers. Read More.
• Neutral Sentiment: Consensus still shows multi-quarter losses (current full‑year consensus ~($2.17) per share), so the stock’s upside depends on continued clinical progress, margin improvement and execution. Read More.
• Neutral Sentiment: Institutional ownership is very high (~95%); while this can stabilize the stock, it may also limit new institutional inflows unless conviction strengthens. Read More.
• Negative Sentiment: CFO Dominic Piscitelli sold 52,000 shares (~$702.5k at ~$13.51), cutting his stake by ~43% — insider selling can be perceived negatively and may temper the rally. SEC Form 4: Read More.

Institutional Investors Weigh In On Oric Pharmaceuticals

Several large investors have recently modified their holdings of ORIC. Nisa Investment Advisors LLC boosted its stake in shares of Oric Pharmaceuticals by 17,300.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,436 shares of the company’s stock valued at $25,000 after purchasing an additional 2,422 shares in the last quarter. Assetmark Inc. purchased a new stake in Oric Pharmaceuticals during the third quarter worth $37,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Oric Pharmaceuticals by 36.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,755 shares of the company’s stock valued at $45,000 after acquiring an additional 1,009 shares in the last quarter. Federation des caisses Desjardins du Quebec boosted its position in Oric Pharmaceuticals by 100.0% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock valued at $33,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its holdings in shares of Oric Pharmaceuticals by 184.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock valued at $37,000 after acquiring an additional 2,936 shares during the period. Institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.